Business Cocktail

Posted on


Boehringer Ingelheim Pharmaceuticals and the Duke Clinical Research Institute have expanded their collaboration to create the largest patient registry for Idiopathic Pulmonary Fibrosis (IPF)
The IPF-PRO Registry will be widened to cover 1500 patients spread over 45 clinical sites which will stimulate understanding of disease progression and patient specific disease outcomes.

BioInvent Inks Mfg. Pact with Global Pharma Firm
BioInvent, a Sweden based company collaborated with Global Pharma Firm to expand its internal and external projects with an estimate revenue generation of SEK 8million.

Elite Pharma, SunGen Pharma in Development and License Agreement
Elite Pharma, entered into an exclusive licensing agreement with SunGen Pharma for the development and commercialization of its four generic products including two CNS stimulants and two beta blockers. Both the US based companies will have marketing rights to two products each whereas Elite Pharma was granted the responsibility of manufacturing and packaging all the four products.

Boehringer and Saniona to Develop new Compounds for Schizophrenia Treatment
Boehringer has partnered with Saniona for the discovery, development, commercialization and manufacture of drugs related to Schizophrenia. Boehringer will pay upto EUR 90 million inclusive of an upfront payment of EUR 5 million, research, development and regulatory milestone payments of upto EUR 50 million and other royalties of upto EUR 35 million on net sales of the commercialized product under the collaboration.

BioLineRx and I-Bridge Capital Establish a New Drug Development Joint Venture in China
BioLineRx and I-Bridge Capital have ventured into iPharma for the development of novel clinical and preclinical therapeutic products in Israel and will provide initial capital of $1 million each. BioLineRx seeks to discover novel therapeutic targets based on Chinese population. The drug will further be in licensed by iPharma for its development and commercialization.

A Research Alliance forms between Harvard and Tata Companies
Tata companies entered a research agreement with Harvard University. The agreement spans a six-year time frame, and has $8.4 million research grant riding on the offer. The boasts of cutting edge research in the labs of the university while keeping the professional development programs under the visiting technology business leaders. This is a unique collaboration, and has been designed to help bring greater benefit of Harvard’s research innovations to the public.

Innovative Targeting Solutions and Johnson & Johnson Innovation collaborate to Advance Drug Discovery
A research collaboration with Janssen Biotech, Inc. (Janssen), was announced by Innovative Targeting Solutions Inc. HuTARG™ research platform of ITS will be utilized by Janssen to discover antibody candidates useful for modulating immune responses in autoimmunity or cancer. The details of the collaboration are not being disclosed at this time.

Advertisements